PRLD Prelude Therapeutics Inc
Price (delayed)
$0.6934
Market cap
$38.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.68
Enterprise value
$39.75M
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective
Highlights
The EPS has increased by 17% year-on-year and by 6% since the previous quarter
Prelude Therapeutics's net income has decreased by 4.4% YoY but it has increased by 3.3% QoQ
The quick ratio has plunged by 51% YoY and by 24% from the previous quarter
The equity has declined by 45% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of PRLD
Market
Valuations
Earnings
Shares outstanding
55.15M
Market cap
$38.24M
Enterprise value
$39.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$146.71M
Net income
-$127.17M
EBIT
-$127.17M
EBITDA
-$123.81M
Free cash flow
-$103.65M
Per share
Balance sheet
Liquidity
EPS
-$1.68
EPS diluted
-$1.68
Free cash flow per share
-$1.37
Book value per share
$2.39
Revenue per share
$0
TBVPS
$2.32
Total assets
$175.52M
Total liabilities
$44.06M
Debt
$18.03M
Equity
$131.46M
Working capital
$110.25M
Debt to equity
0.14
Current ratio
5.3
Quick ratio
5.37
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-60.3%
Return on equity
-74.7%
Return on invested capital
-69.2%
Return on capital employed
-84.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRLD stock price
How has the Prelude Therapeutics stock price performed over time
Intraday
4.9%
1 week
-8.16%
1 month
-23.47%
1 year
-83.09%
YTD
-45.62%
QTD
-45.62%
Financial performance
How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$146.71M
Net income
-$127.17M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 11% year-on-year
Prelude Therapeutics's net income has decreased by 4.4% YoY but it has increased by 3.3% QoQ
Growth
What is Prelude Therapeutics's growth rate over time
Valuation
What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 17% year-on-year and by 6% since the previous quarter
The stock's P/B is 90% below its 5-year quarterly average of 2.8 and 69% below its last 4 quarters average of 0.9
The equity has declined by 45% year-on-year and by 16% since the previous quarter
Efficiency
How efficient is Prelude Therapeutics business performance
PRLD's return on equity is down by 40% year-on-year and by 12% since the previous quarter
The ROA has contracted by 26% YoY and by 8% from the previous quarter
Prelude Therapeutics's ROIC has decreased by 22% YoY and by 9% from the previous quarter
Dividends
What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRLD.
Financial health
How did Prelude Therapeutics financials performed over time
The quick ratio has plunged by 51% YoY and by 24% from the previous quarter
The current ratio has dropped by 51% year-on-year and by 25% since the previous quarter
The debt is 86% lower than the equity
PRLD's debt to equity has surged by 100% year-on-year and by 17% since the previous quarter
The equity has declined by 45% year-on-year and by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.